Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.

Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.

Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.

Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.

Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.

Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.